The present invention relates to a novel oligospirostanoside having the structure 3-0-[.alpha.-L-rhamnopyranosyl-(1.fwdarw.2)-.alpha.-L-rhamnopyranosyl-(1.f wdarw.4)-0-.beta.-D-glucopyranosyl]-25(S)-5.beta.-spirostan-3.beta.-ol isolated from Asparagus racemosus and to a pharmaceutical composition containing the novel oligospirostanoside and to a method for immunomodulation using said oligospirostanoside by administering a pharmaceutically effective amount of said novel oligospirostanoside.

La presente invenzione riguarda un oligospirostanoside del romanzo che ha la struttura 3-0-[.alpha.-L-rhamnopyranosyl-(1.fwdarw.2)-.alpha.-L-rhamnopyranosyl-(1.f wdarw.4)-0-.beta.-D-glucopyranosyl]-25(S)-5.beta.-spirostan-3.beta.-ol isolata dal racemosus dell'asparago e ad una composizione farmaceutica che contiene il oligospirostanoside del romanzo e ad un metodo per il immunomodulation usando il oligospirostanoside detto amministrando una quantità farmaceuticamente efficace di oligospirostanoside detto del romanzo.

 
Web www.patentalert.com

< Sodium ion-driven chloride /bi-carbonate exchanger

< Composition for treatment of infections of humans and animals

> Neuropeptide Y antagonists

> Crystal modification C of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-[4.3. 0]nonan-8-yl)-6-fluoro-1,4-dihyro-4-oxo-3-quinoline carboxylic

~ 00091